Forskning ved Københavns Universitet - Københavns Universitet

Forside

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. / Madsen, Caroline B; Wandall, Hans H; Pedersen, Anders Elm.

I: Immunopharmacology and Immunotoxicology, Bind 35, Nr. 6, 12.2013, s. 649-52.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Madsen, CB, Wandall, HH & Pedersen, AE 2013, 'Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy', Immunopharmacology and Immunotoxicology, bind 35, nr. 6, s. 649-52. https://doi.org/10.3109/08923973.2013.837060

APA

Madsen, C. B., Wandall, H. H., & Pedersen, A. E. (2013). Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. Immunopharmacology and Immunotoxicology, 35(6), 649-52. https://doi.org/10.3109/08923973.2013.837060

Vancouver

Madsen CB, Wandall HH, Pedersen AE. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. Immunopharmacology and Immunotoxicology. 2013 dec;35(6):649-52. https://doi.org/10.3109/08923973.2013.837060

Author

Madsen, Caroline B ; Wandall, Hans H ; Pedersen, Anders Elm. / Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy. I: Immunopharmacology and Immunotoxicology. 2013 ; Bind 35, Nr. 6. s. 649-52.

Bibtex

@article{ddeb6f9b92c34078a14f33e7cfc4b950,
title = "Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy",
abstract = "MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.",
author = "Madsen, {Caroline B} and Wandall, {Hans H} and Pedersen, {Anders Elm}",
year = "2013",
month = "12",
doi = "10.3109/08923973.2013.837060",
language = "English",
volume = "35",
pages = "649--52",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

AU - Madsen, Caroline B

AU - Wandall, Hans H

AU - Pedersen, Anders Elm

PY - 2013/12

Y1 - 2013/12

N2 - MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.

AB - MUC1 is an important target for antibodies in passive cancer immunotherapy. Antibodies against mucin glycans or mucin peptide backbone alone may give rise to cross reactivity with normal tissues. Therefore, attempts to identify antibodies against cancer-specific MUC1 glycopeptide epitopes havebeen made. We recently demonstrated that a monoclonal antibody against the immunodominant Tn-MUC1 (GalNAc-α-MUC1) antigen induced ADCC in breast cancer cell lines, suggesting the feasibility of targeting combined glycopeptide epitopes in future passive cancer immunotherapy.

U2 - 10.3109/08923973.2013.837060

DO - 10.3109/08923973.2013.837060

M3 - Journal article

C2 - 24063621

VL - 35

SP - 649

EP - 652

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 6

ER -

ID: 103647286